Brief: Biovaxys Reports Complete Inhibition Of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein
16/02/2022 13:18
Feb 16 (Reuters) - Biovaxys Technology Corp BIOV.CD :
* BIOVAXYS ANNOUNCES COMPLETE INHIBITION OF ACE-2 BINDING
ACTIVITY
OF HAPTEN-MODIFIED SARS-COV-2 PROTEIN
Source text for Eikon: ID:nPrec34xna
Further company coverage: BIOV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biovaxys Technology
See all newsBrief: Biovaxys Appoints Former Sanofi Vaccines Executive To Board Of Directors
Brief: Biovaxys Announces Life Offering
Brief: Biovaxys And Horizon Technology Finance Execute Amendment To Asset Purchase Agreement
Brief: Biovaxys And Horizon Technology Finance Execute Amendment To Asset Purchase Agreement
Brief: Biovaxys Announces Consolidation And Concurrent Brokered Private Placement Offering For Gross Proceeds Of Up To $3,000,000